Cancer is a leading cause of death worldwide. It is estimated that the burden of cancer will increase up to 22.2 million new cases diagnosed annually worldwide by 2030, which represents an increase by 75% compared with the statistics of 2008 ([@bib14]).

It is now recognised that sporadic cancer is a complex and multifactorial disease involving the contribution and interaction of several genetic and environmental factors. In the recent years, polymorphisms in low-penetrance genes involved in anti-carcinogenic biochemical pathways have been a subject of thorough investigation in the context of identifying the genetic risk factors for cancer development.

The NAD(P)H quinone oxidoreductase 1 enzyme (EC 1.6.5.2), encoded by the *NQO1* gene, which is mapping to chromosomal location 16q22.1, was hypothesised to have a crucial role in the protection against oxidative stress and was shown to be a multifunctional antioxidant and an exceptionally versatile cytoprotector ([@bib23]). Furthermore, recent studies indicated protective roles for NQO1 unrelated to its enzymatic activity and involved in apoptosis, as it was found to act as a stabiliser for the tumor suppressor protein p53 ([@bib4]). [Figure 1](#fig1){ref-type="fig"} summarizes the multiple protective roles of NQO1 known so far.

Several polymorphisms were identified in the *NQO1* gene. However, by far the most commonly studied and the most biochemically influential polymorphism is the C609T polymorphism (dbSNP: rs1800566) at exon 6 of the gene, which results in a proline-to-serine amino-acid change at codon 187 of the protein. The *NQO1* C609T polymorphism was shown to have an established and strong impact on enzymatic activity of the expressed protein by extremely decreasing stability, as the variant enzyme is rapidly ubiquitinated and degraded by the proteasome ([@bib84]). Thus, it was found that homozygosity for the variant T allele results in virtually complete elimination of enzymatic activity (2--4% activity of the wild type), whereas heterozygosity yields decreased enzymatic activity by threefold compared with homozygosity for the wild-type allele ([@bib44]; [@bib84]).

A large number of studies reported the investigation of the role of *NQO1* C609T polymorphism in the susceptibility for developing several types of cancer. However, the results were inconsistent rather than conclusive, possibly due to the small sample size in the majority of studies. Although a few number of meta-analyses were performed in an attempt to overcome the problem of low statistical power in individual studies, these meta-analyses considered individual cancer sites separately ([@bib107]; ([@bib53]; [@bib29]; [@bib111]). Recognised as a global and versatile antioxidant and cytoprotector ubiquitously expressed in all tissues, the gene for NQO1 is proposed to have common roles among all histopathologically different types of cancer arising in different sites or tissues. Therefore, it is biologically plausible to study the effects of polymorphisms in the *NQO1* gene with respect to overall cancer risk. The aim of the present study was to conduct a global meta-analysis to investigate the role of *NQO1* C609T polymorphism with respect to the overall cancer risk, and perform new or updated site-specific meta-analyses involving all common sites of cancer previously investigated in relation to the *NQO1* C609T polymorphism.

Materials and Methods
=====================

Search strategy
---------------

The PubMed database was searched to identify case--control association studies involving cancer and *NQO1* C609T polymorphism. To ensure comprehensive searching, we used only general keywords: 'NQO1\' or 'NADPH:quinone oxidoreductase 1\' and 'Cancer\' and 'polymorphism\' without applying search filters. Articles were retrieved on 17 January 2013. Article searching was repeated independently by searching the Scopus database to compare with the PubMed search results and identify articles not indexed in PubMed. All articles were initially reviewed by abstract and title examination to select for relevant articles, which were subjected to further screening.

Study selection and inclusion/exclusion criteria
------------------------------------------------

Relevant articles were subjected to the following predetermined inclusion criteria: (1) studies investigating the *NQO1* C609T polymorphism with respect to disease susceptibility. (2) Studies with case--control design. (3) Studies including full genotyping data (CC, CT, and TT counts in the case and control groups). (4) Genotype distribution of *NQO1* C609T in the control group is in Hardy--Weinberg equilibrium (HWE). (5) Studies involving adult cancer (childhood leukaemia studies were excluded). (6) Studies involving primary cancer (therapy-related cancer studies were excluded). (7) Studies published in English.

Data extraction
---------------

The following information about the eligible studies was extracted: first author name, year of publication, country of study, ethnicity of studied subjects, tumour site, full genotyping data for the case and control groups, and source of control groups (hospital- or population-based controls). When an article included several ethnic groups or cancer sites, each comparison was treated as a separate study. In a few studies where the racial descent of study subjects was not plainly stated, ethnicity was inferred on the basis of the largest ethnic group inhabiting the country of study.

Statistical analysis
--------------------

We strictly followed published guidelines and recommendations for quality assessment in meta-analyses of genetic association studies ([@bib94]; [@bib61]). (1) We tested five different genetic models and avoided assuming only one 'wrong\' genetic model. (2) Between-study heterogeneity and publication bias were thoroughly assessed. (3) Concordance with HWE was comprehensively tested for all studies. (4) Sensitivity analysis was performed to check for the impact of individual studies or subgroups of studies. (5) Meta-regression analysis was performed to identify any potential source of heterogeneity. (6) The random effects model was utilised to calculate odds ratios and 95% confidence intervals (CIs) whenever moderate-to-high heterogeneity was found.

We tested all relevant studies for concordance of the genotypic distribution of the *NQO1* C609T polymorphism in the control group with the HWE principle using the *χ*^2^-test, and considered *P*-values\<0.05 as statistically significant. Association between the *NQO1* C609T polymorphism and cancer risk was investigated under different genetic models; namely, the dominant (CC *vs* CT+TT), recessive (CC+CT *vs* TT), homozygous codominant (TT *vs* CC), heterozygous codominant (CC *vs* CT) and allele contrast model (C *vs* T). The strength of association was assessed by calculating the odds ratios and 95% confidence intervals and the Z-test was used to evaluate statistical significance with *P*-values\<0.01 considered as statistically significant. Stratified analysis by cancer site, ethnicity, and minor allele frequency (MAF) in controls was conducted. Cancer sites with less than three studies were all grouped under a category termed 'other\' in the overall population analysis. Studies involving mixed populations belonging to different ethnic groups were assigned the 'Mixed\' ethnicity category.

Between-study heterogeneity was assessed using the Cochran\'s Q-test ([@bib20]) by calculating the *P*~heterogeneity~ value, and was quantitated by calculating the *I*^2^ statistic. A random effects model using the DerSimonian and Laird method was used to calculate the OR and 95% CI for comparisons with moderate-to-high heterogeneity (*I*^2^\>25%). Otherwise, a fixed-effects model using the Mantel--Haenszel method was utilised ([@bib74]). Moreover, meta-regression analysis ([@bib97]) was used to identify three possible sources of heterogeneity including ethnicity, tumour site, and MAF.

Sensitivity analysis was performed by sequential omission of individual studies (leave-one-out analysis) and tumour sites for various genetic models in the Asian, Caucasian, and overall population.

Publication bias was evaluated graphically using the Begg\'s funnel plot and statistically using the method of Egger\'s linear regression test ([@bib24]).

Comprehensive Meta-Analysis (Version 2, Biostat, Englewood NJ, USA) and OpenMetaAnalyst (<http://www.cebm.brown.edu/open_meta>) were used for statistical analyses.

Results
=======

Characteristics of retrieved studies
------------------------------------

Systematic screening was performed to identify relevant and eligible studies ([Figure 2](#fig2){ref-type="fig"}). PubMed search returned 251 articles (retrieved on 17 January 2013). Initial examination involving abstracts and titles lead to the exclusion of 130 non-relevant articles. Of the remaining 121 relevant articles, 15 articles were found to lack complete genotyping data, 8 articles were published in other languages than English, 12 articles involved childhood leukaemia, and 5 articles involved secondary cancer. As a result, 81 articles including 97 studies (comparisons) were found to be eligible ([Table 1](#tbl1){ref-type="table"}). Upon testing for concordance with the HWE principle, five studies were found to deviate from HWE and were excluded. Finally, a total of 76 articles involving 92 studies and 21 178 cases and 25 157 controls were included. Scopus searching did not return any additional eligible studies not indexed in PubMed. About 80% of studies involved either Caucasian or Asian populations. There were 50 studies on Caucasian populations, 24 on Asians, 6 studies on Indians, 4 studies on Arabs, 2 studies on African Americans, 2 studies on Turks, and single studies on Persian, Hawaiian, Hispanic, and mixed populations.

Quantitative synthesis
----------------------

We observed significant variation of the T allele frequency across different ethnicities in healthy controls ([Figure 3](#fig3){ref-type="fig"}). Statistically significant association was found for the total population when all studied cancer sites were combined, and under all studied genetic models ([Table 2](#tbl2){ref-type="table"}), with the strongest association found under the TT *vs* CC model (OR=1.18 (1.07--1.31), *P*=0.002). On stratification by ethnicity, we found statistically significant associations for the Caucasian subgroup under all genetic models with the strongest association found under the TT *vs* CC model (OR=1.28 (1.12--1.46), *P*=0.0002). Stratification by cancer site revealed statistically significant associations for bladder cancer (for the TT *vs* CC model, OR=1.48 (1.14--1.93), *P*=0.003), and gastric cancer (for the dominant model, OR=1.34 (1.09--1.65), *P*=0.006) ([Table 2](#tbl2){ref-type="table"}).

We investigated the interaction between the two major ethnic groups (Caucasian and Asian) and cancer site with respect to the effects of *NQO1* C609T on cancer susceptibility ([Table 3](#tbl3){ref-type="table"}). Significant association was found for bladder cancer in Asians (for the TT *vs* CC model, OR=1.70 (1.17--2.46), *P*=0.005).

Test of heterogeneity and meta-regression analysis
--------------------------------------------------

Heterogeneity tests for the total group involving combined cancer sites showed statistically significant (*P*~heterogeneity~\<0.05) but quantitatively moderate heterogeneity with *I*^2^ values\<50% ([Table 2](#tbl2){ref-type="table"}). However, when stratified by ethnicity, heterogeneity was found statistically insignificant and quantitatively low for the Caucasian subgoup (*I*^2^ values\<25%), except for the heterozygous codominant model (*I*^2^=26%) ([Table 2](#tbl2){ref-type="table"}). Furthermore, the homozygous codominant (TT *vs* CC) and the recessive (TT *vs* CT+CC) models showed extremely low heterogeneity in Caucasians (*I*^2^=1%) indicating generally consistent findings among studies in these populations. By contrast, tests for the Asian subgroup showed statistically significant and quantitatively moderate-to-high heterogeneity, which pointed to the Asian ethnicity as an important source of heterogeneity. This was confirmed by meta-analysis regression ([Table 4](#tbl4){ref-type="table"}), which identified the Asian subgroup as a major source of heterogeneity relative to the Caucasian subgroup (*P*=0.03). This was also supported by general examination of the forest plot ([Figure 4](#fig4){ref-type="fig"}) where it was evident that the majority of Caucasian studies yielded consistently odds ratios \>1 for the TT *vs* CC model (indicating increased risk for the TT homozygous genotype), whereas Asian studies yielded more scattered odds ratios. Additionally, when the MAF in controls were grouped into 'high\' (\>35%) or 'low\' (\<35%) categories, the 'high\' MAF subgroup, which correlates with the Asian subgroup ([Figure 3](#fig3){ref-type="fig"}), was found to be a significant source of heterogeneity relative to the 'low\' MAF subgroup (*P\<*0.001). MAF was also examined as a continuous variable and was confirmed to be a major source of heterogeneity as indicated by the regression plot ([Figure 5](#fig5){ref-type="fig"}) and *P*-value of \<0.001 ([Table 4](#tbl4){ref-type="table"}).

Sensitivity analysis
--------------------

Single studies or single tumour sites were sequentially excluded from the meta-analysis to investigate the relative weights of individual studies or data sets. The odds ratios and *P*-values were not statistically altered indicating that the meta-analysis was generally robust.

Publication bias
----------------

Publication bias was assessed for the two most commonly investigated genetic models (homozygous codominant and allele contrast models). The shapes of funnel plots did not indicate any evidence of significant asymmetry ([Figure 6](#fig6){ref-type="fig"}). In addition, the Egger\'s test did not yield any evidence of publication bias (*t*=0.97, *P*=0.33, for TT *vs* CC, and *t*=0.28, *P*=0.78 for T *vs* C).

Discussion
==========

Our meta-analysis included 92 studies and involved 21 178 cases and 25 157 controls. Although all common cancer sites except for bladder and stomach cancers showed no statistically significant association, the combined analysis showed that the variant T allele of *NQO1* C609T polymorphism is strongly associated with overall cancer risk in the total population. Stratification by ethnicity revealed that association is significant for the Caucasian populations, which comprised the largest part of available studies on the subject, but not for the Asian ethnicity, which was another largely represented ethnicity in the available studies. Furthermore, although heterogeneity for the total group was only moderate, as shown by *I*^2^ values in [Table 2](#tbl2){ref-type="table"}, we identified the Asian ethnicity studies as the major source of heterogeneity observed. The high MAF (\>35%), which strongly correlates with the Asian ethnicity, as can be seen in [Figure 3](#fig3){ref-type="fig"}, was also a major source of heterogeneity.

The C609T is one of very few known and common single-nucleotide polymorphisms that completely eliminate enzymatic activity, and its biological impact *in vivo* is undoubted. The NQO1 enzyme has been increasingly attracting attention in cancer and more roles unrelated to its classical metabolic functions ([Figure 7](#fig7){ref-type="fig"}) are being constantly discovered ([Figure 1](#fig1){ref-type="fig"}). First, the NQO1 enzyme has the classical role of catalysing the obligatory two-electron reduction of a broad range of exogenous and endogenous quinones to their respective hydroquinones, preventing the one-electron reduction of these compounds into semiquinones and a variety of reactive oxygen species ([@bib40]; [@bib13]). Second, NQO1 was shown to have an additional antioxidant effect by directly and independently scavenging superoxides ([@bib85]), a function that is shared with superoxide dismutase. Third, the NQO1 was found to maintain the integrity of microtubule cytoskeleton ([@bib103]), although the exact mechanism by which NQO1 functions in this respect is yet to be established. Fourth, the NQO1 enzyme was recently found to act as a stabiliser for several tumour suppressor proteins (p53, p73, and p33), and this stabilisation was shown to be especially prominent under conditions of oxidative stress ([@bib4], [@bib5]). As the C609T polymorphism principally affects the susceptibility of the enzyme to degradation *in vivo*, it affects all aspects of NQO1 function indistinguishably. The overall results of our meta-analysis showed that the variant T allele, which eliminates enzymatic activity, is a susceptibility allele that is compatible with the multiple NQO1 functions described above.

The largest role of NQO1 in cancer susceptibility is attributable to the interaction of the enzyme with environmental exposure. The high MAF of the C609T polymorphism of this 'environmental\' enzyme in the Asian population (\>35%) compared with the Caucasian population (\<20%) suggests that the environmental exposure is widely different among the two populations. In other words, it can be inferred from the difference in MAF, on the basis of natural selection principles, that the rare allele carriers in the Asian populations are not as in disfavour as their counterparts in Caucasian populations. The variation in allele frequency of this polymorphism therefore highlights major environmental differences among the two populations and may in turn partly explain why a significant association was found in Caucasians but not in Asians. Another possible explanation is the widely different genetic structure between the two populations, as the overall effects of *NQO1* C609T polymorphism on cancer susceptibility might be overshadowed or compensated by variants in other metabolic genes ([@bib34]; [@bib73]; [@bib110]). We avoided stratification for other ethnicities due to the very limited number of available studies.

Although most individual studies on Caucasian populations statistically failed to establish an association, it can be seen from the forest plot ([Figure 4](#fig4){ref-type="fig"}) that the results of the overwhelming majority of individual studies in Caucasians consistently indicated that the rare allele was a susceptibility factor, as shown by odds ratios \>1 for the majority of studies. The lack of statistical association despite the consistency in results among these studies might be due to the low MAF in these populations, as it is difficult from a statistical point of view to establish mild-to-moderate associations with low-frequency alleles because this requires extremely elevated sample sizes. Our meta-analysis may have overcome this problem of low statistical power by combining studies involving all common cancer sites. Combining all common cancer sites seems biologically plausible given the fact that the metabolic ([Figure 7](#fig7){ref-type="fig"}) and non-metabolic effects of this enzyme apply in all common cancer sites.

While evidence about the multiple protective roles of the NQO1 enzyme in cancer has been continuously emerging, it should be noted that NQO1 may have adverse effects in some cases. For example, it was found that the NQO1 may bioactivate procarcinogenic coumpounds such as certain nitroaromatic compounds and heterocyclic amines, present in tobacco smoke and certain processed foods ([@bib12]; [@bib18]; [@bib75]). Determination of the nature of environmental exposure becomes more important in this context, as the variant T allele that eliminates enzymatic activity would be expected to exert protective effects under such conditions. Indeed, few studies reported protective effects for the TT homozygous genotype in Asian populations for lung cancer ([@bib17]; [@bib95]), and the nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), which was found to induce lung adenocarcinoma in rodents ([@bib67]; [@bib37]; [@bib33]), and is bioactivated by NQO1, was shown to exist in variable amounts in cigarettes of different brands/geographical origins ([@bib28]). This may contribute to the heterogeneity of the effects of *NQO1* C609T polymorphism in lung cancer.

The duality of NQO1 function in detoxifying and bioactivating carcinogens, the manifestation of which is obviously governed by specific environmental patterns, can explain the high heterogeneity observed in Asian populations in the present meta-analysis. The high environmental heterogeneity for the Asian subgroup may in turn explain the observed overall lack of association observed in our meta-analysis for this ethnicity. Our meta-analysis did not include studying the interaction between specific environmental factors and *NQO1* C609T polymorphism due to the lack of data in the published reports. More information about environmental exposure patterns in the Asian populations is important to resolve the source of heterogeneity observed in the present meta-analysis and assess the true effects of this polymorphism in these populations.

Although our results support firm conclusions about the association between the *NQO1* C609T polymorphism and total cancer risk and especially in the Caucasian subgroup, where very low heterogeneity and high consistency among studies were found, three major points are worth consideration in the present meta-analysis. First, the calculated odds ratios in the present meta-analysis were necessarily crude unadjusted odds ratios, as information about potential confounders, especially environmental exposure patterns, were rarely found in the individual studies. Second, our lack of association results with respect to certain individual cancer sites should be approached with caution because of the small sample sizes available in the published studies. Finally, the statistical problems of multiple testing in such comprehensive meta-analyses involving a very large number of statistical tests should be considered. Examination of [Tables 2](#tbl2){ref-type="table"} and [3](#tbl3){ref-type="table"} shows that the total number of statistical tests performed was 165. However, we attempted to approach this issue rationally by only correcting for the number of genetic models tested through dividing the conventional cut-off *P*-value of 0.05 by the number of genetic models tested (five models). Hence, a cut-off *P*-value of 0.01 was considered. We did not correct for the number of cancer sites investigated, as we believe each cancer site should be tested independently, similarly to conducting individual meta-analyses involving single cancer sites. Although there has been some debate about the topic of correcting for multiple testing, we agree about the notion that exaggeration in correcting for multiple testing is as likely to harm scientific evidence as the lack of it, as it may negate true positive associations ([@bib72]; [@bib43]).

Conclusion
==========

The present comprehensive meta-analysis suggests the *NQO1* C609T polymorphism as an important genetic factor in the overall risk for developing cancer, especially in Caucasian populations. More case--control association studies are needed to support this finding in individual cancer sites and in various ethnic groups.
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###### Database of relevant studies in the meta-analysis

  **First author**[a](#t1-fn2){ref-type="fn"}/**Year**   **Cancer site**[b](#t1-fn3){ref-type="fn"}   **Country**    **Ethnicity**[c](#t1-fn4){ref-type="fn"}    **Study design**  **Cases/controls**   **Case (CC/CT/TT),** ***T*****%**   **Control (CC/CT/TT),** ***T*****%**   **HW** ***P*****-value (control)**
  ------------------------------------------------------ -------------------------------------------- -------------- ------------------------------------------ ------------------ -------------------- ----------------------------------- -------------------------------------- ------------------------------------
  [@bib87]                                               Breast                                       India          Indian                                             PB         200/200              (45/131/24), 0.45                   (34/149/17), 0.46                      0
  [@bib6]                                                Breast                                       USA            Caucasian                                          PB         564/1212             (369/177/18), 0.19                  (824/347/41), 0.18                     0.55
  [@bib30]                                               Breast                                       Japan          Asian                                              HB         237/640              (100/103/34), 0.36                  (240/286/114), 0.40                    0.17
  [@bib86]                                               Breast                                       USA            Caucasian                                          PB         346/235              (222/115/9), 0.19                   (168/61/6), 0.16                       0.87
  [@bib45]                                               Breast                                       Syria          Arab                                               PB         122/139              (71/41/10), 0.25                    (87/43/9), 0.22                        0.25
  [@bib81]                                               Breast                                       Czech          Caucasian                                          PB         238/310              (166/55/17), 0.19                   (221/83/6), 0.15                       0.58
  [@bib38]                                               Breast                                       USA            Caucasian                                          PB         496/495              (325/157/14), 0.19                  (323/151/21), 0.19                     0.53
  [@bib60]                                               Breast                                       Austria        Caucasian                                          PB         218/424              (133/76/9), 0.22                    (290/126/8), 0.17                      0.18
  [@bib48]                                               Head and neck                                USA            Caucasian                                          HB         724/1226             (484/209/31), 0.19                  (805/388/33), 0.19                     0.09
  [@bib32]                                               Head and neck                                Germany        Caucasian                                          HB         295/296              (199/84/12), 0.18                   (197/87/12), 0.19                      0.54
  [@bib90]                                               Head and neck                                Czech/Poland   Caucasian                                          HB         116/121              (92/21/3), 0.12                     (83/35/3), 0.17                        0.76
  [@bib10]                                               Head and neck                                USA/Canada     Caucasian                                          HB         350/366              (245/94/11), 0.17                   (249/106/11), 0.17                     0.94
  [@bib11]                                               Head and neck                                Finland        Caucasian                                          HB         250/172              (143/94/13), 0.24                   (105/62/5), 0.21                       0.24
  [@bib88]                                               Head and neck                                Saudi Arabia   Arab                                               PB         49/504               (30/18/1), 0.20                     (295/177/32), 0.24                     0.43
  [@bib71]                                               Bladder                                      USA            Caucasian                                          HB         232/239              (142/82/8), 0.21                    (163/66/10), 0.18                      0.32
  [@bib82]                                               Bladder                                      Germany        Caucasian                                          PB         99/260               (68/26/5), 0.18                     (195/61/4), 0.13                       0.76
  [@bib79]                                               Bladder                                      Sweden         Caucasian                                          PB         299/124              (206/85/8), 0.17                    (83/34/7), 0.19                        0.18
  [@bib96]                                               Bladder                                      USA            Caucasian                                          HB         235/214              (156/70/9), 0.19                    (150/58/6), 0.16                       0.89
  [@bib39]                                               Bladder                                      Italy          Caucasian                                          HB         201/214              (113/75/13), 0.25                   (135/66/13), 0.21                      0.21
  [@bib63]                                               Bladder                                      Argentina      Hispanic                                           PB         106/108              (62/35/9), 0.25                     (61/40/7), 0.25                        0.9
  [@bib70]                                               Bladder                                      India          Indian                                             HB         104/120              (44/53/7), 0.32                     (70/44/6), 0.23                        0.79
  [@bib102]                                              Bladder                                      Taiwan         Asian                                              HB         300/300              (70/148/82), 0.52                   (94/136/70), 0.46                      0.13
  [@bib19]                                               Bladder                                      Korea          Asian                                              HB         177/170              (81/68/28), 0.35                    (94/60/16), 0.27                       0.17
  [@bib15]                                               Bladder                                      Sweden         Caucasian                                          PB         61/156               (43/13/5), 0.19                     (107/46/3), 0.17                       0.44
  [@bib65]                                               Cervical                                     Japan          Asian                                              HB         124/117              (76/26/22), 0.28                    (69/29/19), 0.29                       0
  [@bib66]                                               Cervical                                     Japan          Asian                                              HB         131/320              (50/54/27), 0.41                    (134/139/47), 0.36                     0.27
  [@bib109]                                              Gastric                                      China          Asian                                              PB         124/165              (40/55/29), 0.46                    (52/86/27), 0.42                       0.39
  [@bib30]                                               Gastric                                      Japan          Asian                                              HB         143/640              (48/71/24), 0.42                    (240/286/114), 0.40                    0.08
  [@bib56]                                               Gastric                                      India          Indian                                             HB         107/195              (51/38/18), 0.35                    (112/68/15), 0.25                      0.31
  [@bib80]                                               Gastric                                      Germany        Caucasian                                          PB         320/252              (200/110/10), 0.20                  (185/63/4), 0.14                       0.6
  [@bib52]                                               Hepatocellular                               China          Asian                                              HB         476/526              (138/220/118), 0.48                 (191/235/100), 0.41                    0.07
  [@bib1]                                                Hepatocellular                               Turkey         Turk                                               HB         167/167              (86/71/10), 0.27                    (96/62/9), 0.24                        0.81
  [@bib26]                                               Ovarian                                      USA            Caucasian                                          HB         928/1035             (579/319/30), 0.20                  (695/308/32), 0.18                     0.76
  [@bib68]                                               Ovarian                                      USA            Caucasian                                          PB         123/182              (82/33/8), 0.20                     (120/55/7), 0.19                       0.82
  [@bib31]                                               Colorectal                                   Germany        Caucasian                                          PB         323/205              (209/102/12), 0.20                  (135/62/8), 0.19                       0.79
  [@bib78]                                               Colorectal                                   India          Indian                                             HB         86/160               (53/29/4), 0.22                     (116/39/5), 0.15                       0.45
  [@bib64]                                               Colorectal                                   Japan          Asian                                              PB         684/777              (259/336/89), 0.38                  (282/392/103), 0.38                    0.07
  [@bib30]                                               Colorectal                                   Japan          Asian                                              HB         146/640              (61/68/17), 0.35                    (240/286/114), 0.40                    0.08
  [@bib76]                                               Colorectal                                   UK             Caucasian                                          PB         490/593              (316/157/17), 0.19                  (398/173/22), 0.18                     0.56
  [@bib9]                                                Colorectal                                   Canada         Caucasian                                          PB         298/349              (201/79/18), 0.19                   (239/102/8), 0.17                      0.45
  [@bib99]                                               Colorectal                                   Netherlands    Caucasian                                          PB         369/415              (225/134/10), 0.21                  (292/112/11), 0.16                     0.95
  [@bib36]                                               Colorectal                                   Czech          Caucasian                                          PB         495/495              (346/134/15), 0.17                  (344/138/13), 0.17                     0.85
  [@bib100]                                              Oesophageal                                  Germany        Caucasian                                          HB         140/260              (91/42/7), 0.20                     (185/65/10), 0.16                      0.17
  [@bib80]                                               Oesophageal                                  Germany        Caucasian                                          PB         61/252               (30/29/2), 0.27                     (185/63/4), 0.14                       0.6
  [@bib59]                                               Oesophageal                                  Iran           Persian                                            HB         93/50                (51/35/7), 0.26                     (22/24/4), 0.32                        0.47
  [@bib22]                                               Oesophageal                                  UK             Caucasian                                          HB         141/93               (96/43/2), 0.17                     (55/33/5), 0.23                        0.99
  [@bib108]                                              Oesophageal                                  Germany        Caucasian                                          PB         257/252              (183/56/18), 0.18                   (185/63/4), 0.14                       0.6
  [@bib108]                                              Oesophageal                                  China          Asian                                              PB         193/141              (51/92/50), 0.50                    (48/70/23), 0.41                       0.77
  [@bib98]                                               Oesophageal                                  India          Indian                                             HB         200/200              (92/93/15), 0.31                    (93/86/21), 0.32                       0.87
  [@bib57]                                               Oesophageal                                  India          Indian                                             HB         135/195              (68/43/24), 0.34                    (112/68/15), 0.25                      0.31
  [@bib30]                                               Oesophageal                                  Japan          Asian                                              HB         102/640              (37/52/13), 0.38                    (240/286/114), 0.40                    0.08
  [@bib89]                                               Lung                                         Denmark        Caucasian                                          PB         254/267              (162/83/9), 0.20                    (176/80/11), 0.19                      0.62
  [@bib105]                                              Lung                                         Korea          Asian                                              HB         314/347              (110/158/46), 0.4                   (120/166/61), 0.41                     0.78
  [@bib21]                                               Lung                                         USA            Caucasian                                          PB         387/405              (271/97/19), 0.17                   (271/119/15), 0.18                     0.67
  [@bib50]                                               Lung                                         China          Asian                                              HB         95/136               (12/63/20), 0.54                    (41/73/22), 0.43                       0.27
  [@bib47]                                               Lung                                         UK             Caucasian                                          HB         82/145               (56/24/2), 0.17                     (111/32/2), 0.12                       0.86
  [@bib104]                                              Lung                                         USA            Caucasian                                          HB         780/1096             (513/246/21), 0.18                  (715/341/40), 0.19                     0.93
  [@bib104]                                              Lung                                         USA            Mixed                                              HB         34/78                (18/14/2), 0.26                     (20/41/17), 0.48                       0.64
  [@bib106]                                              Lung                                         China          Asian                                              HB         84/84                (28/39/17), 0.43                    (26/41/17), 0.45                       0.91
  [@bib49]                                               Lung                                         Taiwan         Asian                                              HB         198/332              (57/141/0), 0.36                    (95/237/0), 0.36                       0
  [@bib30]                                               Lung                                         Japan          Asian                                              HB         192/640              (87/71/34), 0.36                    (240/286/114), 0.40                    0.26
  [@bib11]                                               Lung                                         Finland        Caucasian                                          HB         150/172              (85/55/10), 0.25                    (105/62/5), 0.21                       0.24
  [@bib3]                                                Lung                                         Sweden         Caucasian                                          PB         524/530              (345/168/11), 0.18                  (368/153/9), 0.16                      0.12
  [@bib21]                                               Lung                                         USA            African-American                                   PB         113/121              (77/32/4), 0.18                     (79/36/6), 0.20                        0.48
  [@bib29]                                               Lung                                         China          Asian                                              HB         681/597              (187/326/168), 0.49                 (172/281/144), 0.48                    0.17
  [@bib77]                                               Lung                                         USA            Caucasian                                          PB         683/683              (454/205/24), 0.19                  (480/186/17), 0.16                     0.84
  [@bib77]                                               Lung                                         USA            African-American                                   PB         36/36                (15/17/4), 0.35                     (15/14/7), 0.39                        0.28
  [@bib77]                                               Lung                                         USA            Caucasian                                          PB         107/107              (67/33/7), 0.22                     (69/35/3), 0.19                        0.56
  [@bib17]                                               Lung                                         USA            Asian                                              PB         109/167              (54/48/7), 0.28                     (64/78/25), 0.38                       0.88
  [@bib17]                                               Lung                                         USA            Caucasian                                          PB         135/171              (81/49/5), 0.22                     (105/62/4), 0.20                       0.14
  [@bib17]                                               Lung                                         USA            Hawaiian                                           PB         83/102               (61/18/4), 0.16                     (60/39/3), 0.22                        0.26
  [@bib46]                                               Lung                                         China          Asian                                              PB         119/109              (37/57/25), 0.45                    (32/54/23), 0.46                       0.98
  [@bib16]                                               Lung                                         China          Asian                                              HB         75/162               (25/37/13), 0.42                    (45/83/34), 0.47                       0.71
  [@bib95]                                               Lung                                         Japan          Asian                                              HB         198/152              (83/93/22), 0.35                    (52/77/23), 0.40                       0.53
  [@bib27]                                               Leukemia                                     Russia         Caucasian                                          PB         83/177               (52/28/3), 0.20                     (119/52/6), 0.18                       0.91
  [@bib35]                                               Leukaemia                                    Japan          Asian                                              HB         51/476               (13/31/7), 0.44                     (200/201/75), 0.37                     0.04
  [@bib8]                                                Leukaemia                                    Canada         Caucasian                                          HB         323/299              (219/93/11), 0.18                   (196/96/7), 0.18                       0.23
  [@bib69]                                               Leukaemia                                    Tunisia        Arab                                               PB         100/106              (46/45/9), 0.32                     (66/32/8), 0.23                        0.15
  [@bib101]                                              Leukaemia                                    Italy          Caucasian                                          PB         157/155              (101/48/8), 0.20                    (108/40/7), 0.17                       0.2
  [@bib83]                                               Leukaemia                                    UK             Caucasian                                          PB         134/175              (95/30/9), 0.18                     (110/53/12), 0.22                      0.12
  [@bib41]                                               Multiple myeloma                             Korea          Asian                                              PB         114/163              (37/70/7), 0.37                     (50/80/33), 0.45                       0.92
  [@bib51]                                               Multiple myeloma                             Australia      Caucasian                                          PB         100/201              (60/36/4), 0.22                     (142/56/3), 0.15                       0.34
  [@bib55]                                               Multiple myeloma                             Italy          Caucasian                                          PB         245/124              (149/82/14), 0.22                   (77/40/7), 0.22                        0.55
  [@bib82]                                               Renal cell carcinoma                         Germany        Caucasian                                          PB         131/260              (84/44/3), 0.19                     (195/61/4), 0.13                       0.76
  [@bib54]                                               Renal cell carcinoma                         France         Caucasian                                          HB         173/210              (102/60/11), 0.24                   (136/66/8), 0.20                       1
  [@bib30]                                               Lymphoma                                     Japan          Asian                                              HB         108/640              (40/51/17), 0.39                    (240/286/114), 0.40                    0.08
  [@bib27]                                               Lymphoma                                     Russia         Caucasian                                          PB         76/177               (54/20/2), 0.16                     (119/52/6), 0.18                       0.91
  [@bib42]                                               Lymphoma                                     Korea          Asian                                              HB         713/1689             (234/362/117), 0.42                 (585/850/254), 0.40                    0.054
  [@bib2]                                                Lymphoma                                     Saudi Arabia   Arab                                               PB         150/504              (94/37/19), 0.25                    (295/177/32), 0.24                     0.43
  [@bib7]                                                Pancreatic                                   USA/Europe     Caucasian                                          HB         81/76                (53/21/7), 0.22                     (46/24/6), 0.24                        0.27
  [@bib62]                                               Pancreatic                                   Czech          Caucasian                                          HB         235/265              (164/64/7), 0.17                    (187/71/7), 0.16                       0.93
  [@bib30]                                               Prostate                                     Japan          Asian                                              HB         56/640               (17/30/9), 0.43                     (240/286/114), 0.40                    0.08
  [@bib58]                                               Prostate                                     India          Indian                                             HB         195/250              (105/67/23), 0.29                   (164/72/14), 0.20                      0.11
  [@bib91]                                               Prostate                                     Germany        Caucasian                                          PB         248/492              (163/80/5), 0.18                    (333/133/26), 0.19                     0.01
  [@bib25]                                               Prostate                                     Turkey         Turk                                               HB         45/59                (23/17/5), 0.30                     (23/26/10), 0.39                       0.57
  [@bib93]                                               Prostate                                     Germany        Caucasian                                          HB         119/232              (76/37/6), 0.21                     (166/60/6), 0.16                       0.84
  [@bib92]                                               Prostate                                     Germany        Caucasian                                          PB         54/100               (37/15/2), 0.18                     (67/31/2), 0.18                        0.46

Abbreviations: HB=hospital-based, PB=population-based.

Reference are provided in the list of references. Five studies not in HW (*P*\<0.05) were excluded from the meta-analysis.

The head and neck cancer category includes oral, laryngeal, pharyngeal and thyroid cancers.

The ethnicity 'Asian\' was used to refer to populations inhabiting eastern Asia.

###### Association between *NQO1* C609T polymorphism and cancer susceptibility based on tumour location and ethnicity under different genetic models

                                             **TT** ***vs*** **CC**          **TC** ***vs*** **CC**   **TT** ***vs*** **TC+CC**   **TT+TC** ***vs*** **CC**       **T** ***vs*** **C**                                                                                                                                                  
  --------------------- ---- --------------- ------------------------------- ------------------------ --------------------------- ------------------------------- ---------------------- ---- ------------------------------- -------- ---- -------------------------------- -------- ---- ----------------------------------- -------- ----
  **Site**                                                                                                                                                                                                                                                                                                                              
  Breast                7    2221/3455       1.19 (0.76--1.85), 0.45         0.02                     59                          1.10 (0.97--1.24), 0.13         0.36                   9    1.16 (0.76--1.77), 0.5          0.03     57   1.10 (0.98--1.23), 0.11          0.25     23   1.09 (0.95--1.26), 0.2              0.08     47
  Head and Neck         6    1784/2685       1.24 (0.88--1.74), 0.22         0.57                     0                           0.91 (0.79--1.04), 0.18         0.57                   0    1.27 (0.91--1.78), 0.17         0.58     0    0.94 (0.82--1.07), 0.35          0.54     0    0.98 (0.88--1.10), 0.73             0.47     0
  Bladder               10   1814/1905       **1.48 (1.14--1.93), \<0.01**   0.30                     16                          **1.26 (1.08--1.46), \<0.01**   0.47                   0    1.29 (1.01--1.64), 0.12         0.28     17   **1.29 (1.12--1.48), \<0.01**    0.51     0    **1.23 (1.10**--**1.38), \<0.01**   0.58     0
  Gastric               4    694/1252        1.55 (1.00--2.41), 0.05         0.23                     31                          1.25 (0.96--1.62), 0.09         0.25                   27   1.49 (0.94--2.35), 0.09         0.14     44   **1.34 (1.09--1.65),\<0.01**     0.32     15   1.29 (1.05--1.58), 0.02             0.16     42
  Colorectal            8    2891/3634       0.99 (0.80--1.23), 0.95         0.23                     25                          1.08 (0.94--1.25), 0.29         0.13                   37   0.99 (0.80--1.21), 0.91         0.24     24   1.08 (0.94--1.24), 0.28          0.12     39   1.06 (0.94--1.20), 0.33             0.08     44
  Oesophageal           9    1322/2083       1.35 (0.81--2.26), 0.25         \<0.01                   63                          1.12 (0.89--1.42), 0.34         0.04                   50   1.29 (0.78--2.12), 0.32         \<0.01   64   1.17 (0.93--1.49), 0.19          0.02     56   1.16 (0.94--1.44), 0.17             \<0.01   67
  Lung                  22   5235/6307       0.96 (0.78--1.18), 0.7          0.06                     35                          0.97 (0.87--1.09), 0.64         0.04                   38   0.96 (0.84--1.10), 0.57         0.42     3    0.97 (0.86--1.09), 0.57          \<0.01   47   0.97 (0.89--1.07), 0.57             0.01     45
  Leukaemia             5    797/912         1.21 (0.76--1.92), 0.41         0.92                     0                           1.10 (0.77--1.55), 0.61         0.04                   60   1.17 (0.74--1.84), 0.5          0.98     0    1.10 (0.80--1.52), 0.54          0.06     56   1.08 (0.87--1.35), 0.48             0.17     38
  Multiple myeloma      3    459/488         0.88 (0.25--3.11), 0.84         0.02                     75                          1.23 (0.92--1.64), 0.17         0.59                   0    0.80 (0.22--2.92), 0.74         0.01     77   1.15 (0.87--1.52), 0.14          0.28     22   1.03 (0.68--1.58), 0.88             0.02     73
  Lymphoma              4    1047/3010       1.17 (0.94--1.46), 0.17         0.35                     9                           0.94 (0.74--1.18), 0.58         0.21                   33   1.19 (0.82--1.73), 0.36         0.14     45   1.02 (0.88--1.18), 0.08          0.60     0    1.04 (0.94--1.16), 0.43             0.80     0
  Prostate              5    469/1281        1.48 (0.82--2.67), 0.19         0.18                     36                          1.25 (0.98--1.61), 0.08         0.40                   2    1.34 (0.79--2.29), 0.28         0.22     30   1.26 (0.93--1.70), 0.14          0.20     33   1.19 (0.90--1.58), 0.23             0.08     52
  Other                 9    2445/3041       1.45 (1.16--1.81), \<0.01       0.96                     0                           1.20 (1.07--1.35), \<0.01       0.60                   0    1.34 (1.09--1.65), \<0.01       0.98     0    1.23 (1.10--1.38), \<0.01        0.64     0    1.21 (1.10--1.32), \<0.01           0.77     0
  **Ethnicity**                                                                                                                                                                                                                                                                                                                         
  Caucasian             50   13 682/15 613   **1.28 (1.13--1.46), \<0.01**   0.45                     1                           **1.10 (1.03--1.17), \<0.01**   0.05                   26   **1.25 (1.11--1.42), \<0.01**   0.46     1    **1.11 (1.06--1.17), \<0.01**    0.08     23   **1.11 (1.06--1.16), \<0.01**       0.11     20
  Asian                 24   5571/6645       1.02 (0.86--1.20), 0.851        \<0.01                   58                          1.06 (0.93--1.20), 0.39         0.14                   24   0.99 (0.87--1.14), 0.92         \<0.01   47   1.04 (0.94--1.15), 0.47          0.01     44   1.01 (0.94--1.10), 0.73             \<0.01   56
  Other                 18   1925/2899       1.26 (0.91--1.74), 0.158        0.03                     43                          1.04 (0.86--1.25), 0.72         \<0.01                 52   1.26 (0.94--1.69), 0.12         0.06     36   1.07 (0.88--1.30), 0.48          \<0.01   57   1.08 (0.92--1.27), 0.35             \<0.01   61
  **MAF in controls**                                                                                                                                                                                                                                                                                                                   
  \<35                  66   15 669/18 509   **1.35 (1.21--1.51), \<0.01**   0.33                     7                           **1.10 (1.03--1.17), \<0.01**   \<0.01                 32   **1.32 (1.18--1.47), \<0.01**   0.34     6    **1.13 (1.07--1.20), \<0.01**    0.01     30   **1.14 (1.08--1.19), \<0.01**       0.01     30
  \>35                  26   5509/6648       0.95 (0.80--1.13), 0.58         \<0.01                   58                          1.02 (0.92--1.12), 0.71         0.08                   29   0.95 (0.83--1.09), 0.49         \<0.01   45   1.00 (0.89--1.11), 0.98          \<0.01   48   0.98 (0.90--1.06), 0.6              \<0.01   58
  Total                 92   21 178/25 157   **1.18 (1.07--1.31), 0.002**    \<0.01                   36                          **1.08 (1.02--1.13), 0.005**    \<0.01                 32   **1.14 (1.04--1.25), 0.006**    \<0.01   29   **1.10 (1.04--1.15), \<0.001**   \<0.01   38   **1.09 (1.04--1.13), \<0.001**      \<0.01   45

Abbreviations: CI=confidence interval; MAF=minor allele frequency; OR=odds ratio.

Statistically significant associations (*P*\<0.01) are shown in bold.

###### Interaction between cancer site and ethnicity in the effects of NQO1 C609T on cancer susceptibility

                                    **TT** ***vs*** **CC**          **TC** ***vs*** **CC**   **TT** ***vs*** **TC+CC**   **TT+TC** ***vs*** **CC**   **T** ***vs*** **C**                                                                                                                                           
  ---------------- ---- ----------- ------------------------------- ------------------------ --------------------------- --------------------------- ---------------------- ---- ------------------------- -------- ---- ------------------------------- -------- ---- ----------------------------------- -------- ----
  **Caucasian**                                                                                                                                                                                                                                                                                                     
   Breast cancer   5    1862/2676   1.38 (0.75--2.52), 0.3          0.03                     63                          1.14 (0.99--1.30), 0.06     0.38                   4    1.32 (0.72--2.44), 0.37   0.02     65   1.15 (1.01--1.30), 0.03         0.44     0    1.14 (1.00--1.31), 0.05             0.24     27
   Head and neck   5    1735/2181   1.33 (0.94--1.89), 0.11         0.75                     0                           0.91 (0.79--1.04), 0.17     0.44                   0    1.37 (0.97--1.94), 0.08   0.78     0    0.94 (0.82--1.08), 0.38         0.40     0    0.99 (0.88--1.11), 0.87             0.40     1
   Bladder         6    1127/1207   1.32 (0.73--2.36), 0.36         0.11                     44                          1.19 (0.99--1.44), 0.07     0.58                   0    1.26 (0.69--2.30), 0.45   0.09     48   1.20 (1.00--1.43), 0.05         0.69     0    1.16 (1.00--1.36), 0.05             0.57     0
   Colorectal      5    1975/2057   1.25 (0.88--1.78), 0.2          0.41                     0                           1.12 (0.93--1.34), 0.24     0.15                   41   1.21 (0.86--1.72), 0.27   0.33     14   1.13 (0.99--1.29), 0.06         0.27     23   1.12 (1.00--1.26), 0.05             0.44     0
   Oesophageal     4    599/857     1.57 (0.49--5.01), 0.44         0.03                     67                          1.24 (0.74--2.09), 0.42     \<0.01                 77   1.47 (0.48--4.48), 0.5    0.03     65   1.29 (0.78--2.13), 0.32         \<0.01   77   1.27 (0.82--1.94), 0.28             \<0.01   77
   Lung            9    3102/3576   1.19 (0.91--1.57), 0.21         0.52                     0                           1.06 (0.96--1.18), 0.26     0.71                   0    1.18 (0.90--1.55), 0.24   0.53     0    1.07 (0.97--1.19), 0.16         0.68     0    1.07 (0.98--1.17), 0.12             0.59     0
   Leukaemia       3    374/507     1.03 (0.56--1.91), 0.93         0.88                     0                           1.01 (0.66--1.55), 0.96     0.14                   50   1.05 (0.57--1.93), 0.88   0.98     0    1.02 (0.69--1.51), 0.92         0.16     46   1.02 (0.76--1.37), 0.88             0.24     30
   Other           13   2908/3413   1.38 (1.04--1.82), 0.02         0.96                     0                           1.17 (1.05--1.31), \<0.01   0.26                   19   1.33 (1.00--1.75), 0.05   0.98     0    1.19 (1.07--1.33), \<0.01       0.25     19   1.17 (1.07--1.29), \<0.01           0.35     9
  **Asian**                                                                                                                                                                                                                                                                                                         
   Bladder         2    477/470     **1.70 (1.17--2.46), \<0.01**   0.54                     0                           1.40 (1.04--1.88), 0.03     0.73                   0    1.36 (0.99--1.87), 0.06   0.32     0    **1.49 (1.13--1.96), \<0.01**   0.94     0    **1.33 (1.10**--**1.60), \<0.01**   0.51     0
   Gastric         2    267/805     1.18 (0.78--1.79), 0.44         0.52                     0                           1.06 (0.72--1.55), 0.78     0.24                   27   1.17 (0.71--1.94), 0.54   0.18     44   1.10 (0.81--1.49), 0.53         0.52     0    1.09 (0.89--1.34), 0.41             0.75     0
   Colorectal      2    830/1417    0.79 (0.51--1.24), 0.3          0.17                     48                          0.93 (0.77--1.13), 0.49     0.99                   0    0.82 (0.52--1.28), 0.38   0.13     55   0.91 (0.76--1.09), 0.31         0.60     0    0.91 (0.77--1.07), 0.26             0.24     29
   Oesophageal     2    295/781     1.24 (0.46--3.36), 0.67         0.03                     79                          1.20 (0.86--1.69), 0.28     0.89                   0    1.11 (0.43--2.90), 0.83   0.02     81   1.21 (0.88--1.67), 0.24         0.34     0    1.14 (0.75--1.74), 0.54             0.05     73
   Lung            9    1867/2394   0.87 (0.66--1.16), 0.35         0.05                     48                          0.94 (0.75--1.16), 0.55     0.04                   50   0.93 (0.79--1.09), 0.35   0.50     0    0.92 (0.73--1.14), 0.42         0.02     56   0.93 (0.81--1.06), 0.27             0.05     49
   Lymphoma        2    821/2329    1.10 (0.87--1.41), 0.42         0.46                     0                           1.07 (0.89--1.27), 0.49     0.98                   0    1.06 (0.86--1.33), 0.58   0.41     0    1.04 (0.97--1.12), 0.41         0.79     0    1.05 (0.94--1.18), 0.39             0.54     0
   Other           5    1014/2289   0.96 (0.56--1.65), 0.89         \<0.01                   78                          1.12 (0.94--1.33), 0.21     0.36                   8    0.89 (0.55--1.45), 0.65   \<0.01   78   1.11 (0.87--1.14), 0.42         0.10     48   1.03 (0.81--1.30), 0.84             \<0.01   74

Abbreviations: CI=confidence interval; OR=odds ratio.

Statistically significant associations (*P*\<0.01) are shown in bold.

###### Meta-regression analysis identifying potential sources of heterogeneity under the homozygous codominant model (TT *vs* CC)

                      ***n***  **Coefficient**   **Lower bound**   **Upper bound**   ***P***
  ------------------ --------- ----------------- ----------------- ----------------- ---------
  **Site**                                                                           
  Head and neck          6     Ref               ---               ---               ---
  Breast                 7     −0.08             −0.64             0.48              0.78
  Bladder               10     0.19              −0.36             0.74              0.50
  Gastric                4     0.25              −0.38             0.88              0.43
  Colorectal             8     −0.14             −0.69             0.40              0.60
  Oesophageal            9     0.12              −0.44             0.69              0.68
  Lung                  22     −0.23             −0.72             0.25              0.35
  Leukaemia              5     0.005             −0.68             0.69              0.99
  Multiple myeloma       3     −0.49             −1.31             0.32              0.24
  Lymphoma               4     −0.02             −0.62             0.58              0.95
  Prostate               5     0.22              −0.46             0.90              0.52
  Other                  9     0.16              −0.38             0.70              0.57
  **Ethnicity**                                                                      
  Caucasian             50     Ref               ---               ---               ---
  Asian                 24     −0.25             −0.47             −0.03             0.03
  Other                 18     0.015             −0.30             0.32              0.93
  **MAF (con)**                                                                      
                               −1.563            −2.436            −0.689            \<0.001
  Low (\<35%)           66     Ref               ---               ---               ---
  High (\>35%)          26     −0.35             −0.55             −0.15             \<0.001

Abbreviations: MAF, minor allele frequency.
